XXXX developed in the setting of chronic liver disease and @entity82 .

@entity1 @entity650 @entity2163 @entity8055 @entity82 @entity5 @entity4104 @entity384 @entity3546 @entity37164 @entity5448 @entity209 @entity652 @entity2215 @entity285 @entity1851
@entity8055 is considered to occur exclusively in non-fibrotic livers. It is a heterogeneous entity and a molecular classification is now widely accepted. The most frequent hepatocellular @entity652 subtype, namely inflammatory @entity652 , harbor somatic activating mutations of genes involved in the @entity650 pathway that lead to high @entity1851 and serum amyloid A expression. The aim of our study was to investigate a series of @entity5 developed on cirrhotic livers and characterized by an unequivocal histological diagnosis. We performed a clinical, pathological, and molecular study of 10 @entity5 developed in three @entity1 with @entity82 . Markers allowing hepatocellular @entity652 classification were assessed by quantitative real-time PCR and immunohistochemistry. Samples were sequenced for @entity3546 , @entity5448 , @entity37164 , @entity2163 , @entity4104 , and @entity2215 (promoter) mutations. A control series of 32 classical macronodules developed in @entity82 related to various etiologies was screened by immunohistochemistry and gene sequencing. The three @entity1 had @entity82 related to @entity209 and/or @entity285 intake; two had a @entity5 , while the third developed more than 30 lesions. Microscopic examination showed well-differentiated @entity5 sharing features with inflammatory @entity652 including inflammatory infiltrates, @entity384 , and dystrophic vessels. Sequencing revealed classical hotspot somatic mutations ( @entity37164 , n=8; @entity4104 , n=1; and @entity2163 , n=1) known to be responsible for @entity650 /JAK/STAT pathway activation. Two classical high-grade macronodules demonstrated high serum amyloid A and/or @entity1851 expression, without gene mutations. Altogether, our findings support the existence of rare inflammatory @entity652 developed in @entity82 .
